CAR-T cells in the lymph nodes
Engineered cell therapies such as Chimeric Antigen Receptor T cells (CAR-T) have emerged as a powerful therapeutic strategy for cancer treatment with demonstrated efficacy in leukemia and lymphoma. In this approach, T cells collected from a patient are genetically reprogrammed to express surface receptors (CARs) which allow them to specifically recognize tumors. Patients are given large doses of these CAR-expressing T cells which search out tumor cells throughout the body using their CAR to differentiate healthy cells from tumor. This specific recognition process between the CAR and the tumor triggers T cell activation and tumor cell killing.